ACHV · Achieve Life Sciences, Inc.

Track ACHV — free

$6.99 -0.25 (-3.45%) At close · Oct 5

Russell 2000 member Rebalance outlook locked

Market Cap

$771.77M

102.90M

Volume · Oct 5 1.7M Avg daily vol (3M) 1.47M

Up next

Next earnings call

Nov 10, 2026 Est · unconfirmed · in 5 wks

Latest filing: 10-Q

filed Aug 11, 2026

Q1 2026 earnings call transcript

call held May 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+127.0%

Trailing year

Short interest

15.5%

Latest settlement · 9.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.59

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +33%

above

Price vs 50-day avg −3%

below

RSI (14) 43

neutral

MACD trend Negative

52-week position 78%

mid-range

Momentum

relative strength

Strong

1-month return −13%

trailing

6-month return +102%

trailing

YTD return +46%

this year

Relative strength +90%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $7 › 200d $5 — 50d above 200d

Institutional flow Accumulating

1 of 111 funds reported for Sep 30 · net +212 sh shares · +1 new

Insider flow Distributing

Net -$175.2K over 90 days · 100% sells

Short interest Falling

15.54% of float · ▼ -2.8% MoM · 9.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

111 holders — near 3-yr high, broad support

Squeeze score 72

high risk · 0–100

Fundamentals

Poor

EPS growth −1%

Y/Y

Free cash flow $-49.5M

Quant / Vol

risk profile

Very High

Volatility 90%

annualized · 1-yr

Max drawdown −55%

past year

ATR 6.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+33% Bullish

Price vs 50-day avg

−3% Neutral

RSI (14)

43 Neutral

MACD trend

Negative Bearish

52-week position

78% Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $7 › 200d $5 — 50d above 200d

Institutional flow Accumulating

1 of 111 funds reported for Sep 30 · net +212 sh shares · +1 new

Insider flow Distributing

Net -$175.2K over 90 days · 100% sells

Short interest Falling

15.54% of float · ▼ -2.8% MoM · 9.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

111 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $7 · 78% Range high $9

vs 200-day avg +33% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ACHV Achieve Life Sciences, Inc. this stock	$771.77M	+45.7%	—	—	15.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

112

% held: 82.4%
Reported: 1 of 111
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

16.0M

Days to cover: 9.1d
Change: -453.8K sh

View

Short Volume

Short vol %

27%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

16.7K

Value: $118.2K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

49.8%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$175.2K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-54.6M
EPS diluted: $-1.25

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 1, 2026
This year: 13

View

Proposed Sales

Value

$155.1K

Shares: 20.6K
Filed: Aug 19, 2026

View

Exempt Offerings

Offering

$25.0M

Filed: Dec 8, 2022

View

Earnings & Events

Webcasts

Last webcast

Aug 11, 2026

View

Performance

	5D	20D	120D	MTD	YTD
ACHV	-4.0%	-12.9%	+102.2%	-10.5%	+45.7%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-3.8%	-12.4%	+90.1%	-11.4%	+32.8%

Key facts CIK 949858 CUSIP 004468500 13F (30d) 3 filings 3 filers Visit website Investor relations

ACHV · Achieve Life Sciences, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance